2017年乳腺癌新辅助治疗进展

Current perspectives of neoadjuvant therapy for breast cancer in 2017

乳腺癌的新辅助治疗包括在手术之前进行的化疗、内分泌治疗、靶向治疗等。肿瘤组织对于新辅助治疗的反应与疗效密切相关,甚至可能关系到患者治疗后的生存,特别是病理完全缓解(pCR)已经被提出作为临床效益预测的替代终点,新辅助治疗提供的这些信息为下一步治疗方案的制定指明了方向。近年来,对于新辅助治疗的研究不断深入,一些重要临床研究的结果也在不断更新并被重新解读,使我们的理念也在随之改变。在本文中我们简述了2017年有关新辅助治疗方面的新进展。

Neoadjuvant therapy is critical for treatment in patients with breast cancer, including chemotherapy, endocrine therapy, targeted therapy and so on. The response of tumor tissue, especially pathological complete response （PCR） has been proposed as a surrogate endpoint for prediction of long-term clinical benefit.The neoadjuvant therapy also provides information of tumor response and improves further therapeutic strategies. Recently, substantial developments have been made in neoadjuvant therapy with important clinical trials, and our concept of neoadjuvant therapy is also changing. This review showed the current perspectives in neoadjuvant therapy in 2017.